TAIPEI, July 21, 2026 /PRNewswire/ — BIO Asia–Taiwan 2026, Asia’s largest biotechnology gathering jointly organized by Taiwan Bio Industry Organization (Taiwan BIO) and the global Biotechnology Innovation Organization (BIO), concluded successfully on 19th of July, setting new benchmarks for participation and international engagement. The event underscored Taiwan’s emergence as a globally connected biotechnology hub and a trusted partner to the international biotech industry. The conference also advanced regional collaboration by promoting the development of an Asian biotech ecosystem, fostering exchanges and creating new opportunities for future partnerships and business.
BIO Asia–Taiwan 2026 Opening Ceremony gathers biotechnology leaders, government officials, investors, and innovators from around the world, reinforcing Taiwan’s role as a key hub for biotech collaboration in Asia.
Under the theme “Asian Inspiration, Global Impact”, the BIO Asia–Taiwan Exhibition 2026 brought together 22 national delegations, 900 exhibitors, and 2,300 booths, attracting attendees from nearly 60 countries and recording almost 150,000 visits, setting a new record.
BIO Asia–Taiwan Chairman Johnsee Lee noted that Taiwan’s strategic location at the heart of the Asia-Pacific, combined with its thriving electronics industry and biotechnology sector, now generating over NT$800 billion (US$25 billion) in annual revenue, has established the country as a biotech hub within Asia. He added that Taiwan’s rapidly expanding biotech innovation ecosystem has evolved from being home-grown (“In Taiwan”), to expanding overseas (“From Taiwan”), to currently positioning itself as the global biotech industry’s partner of choice (“With Taiwan”).
Lee said BIO Asia–Taiwan has successfully evolved from a regional event into one of Asia’s leading international biotech conferences, with an industry influence comparable to BIO Europe. This year’s conference attracted more than 3,500 biotech professionals, while international attendance and speaker participation reached record highs. BIO Partnering also surpassed 10,000 scheduled meetings, underscoring the event’s role as a gateway for global companies seeking R&D collaborations, CDMO contracts, investment opportunities, and licensing partnerships in Asia.
This year’s exhibition brought together 16 national pavilions, while the conference hosted 10 regional collaboration forums. In addition, the conference facilitated several international partnerships, including the signing of a Master Service Framework Agreement between Poland’s Mabion and Taiwan’s KriSan Biotech.
Lee noted that Taiwan’s biotech industry, driven largely by SMEs and startups, benefits from flexibility and vitality but faces resource constraints. BIO Asia–Taiwan addressed these challenges through forums on AI, fundraising, CDMO, and ADCs, while connecting Asian companies to exchange resources, build partnerships, and strengthen global collaboration.